

## **Korean Intellectual Property Office Issues Patent Notice of Allowance for unique Cymerus™ Technology**

**Melbourne, Australia;** 7 August 2020: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP or “the Company”), announced today that a Notice of Allowance has been received from the Korean Intellectual Property Office (KIPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell technology. The patent application entitled “Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions” is owned by the University of Wisconsin–Madison’s Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed exclusively from WARF to Cynata.

**Dr Ross Macdonald, Cynata’s Chief Executive Officer, said:**

*“We are very pleased that the KIPO has issued this Notice of Allowance for a further patent around our core Cymerus technology. Korea is an important market for regenerative medicine and has been one of the early adopters of stem cell-based therapeutics. This development further strengthens Cynata’s comprehensive patent portfolio and supports our commercialisation activities toward the development of consistent, robust MSC therapeutic products to treat a range of prevalent and devastating diseases worldwide.”*

The Notice of Allowance is sent to the applicant when the KIPO intends to issue a patent. The patent builds on the existing strong IP protection of the Cymerus platform and its unique ability to manufacture mesenchymal stem cells (MSCs) at scale, from a single donation, to create therapeutic stem cell products.

The inventors named on the patent are Professor Igor Slukvin, founder, advisor and shareholder of Cynata, and Dr Gene Uenishi.

Cynata anticipates that the patent will be granted around early November 2020, with an expiration date of 12 March 2034.

**-ENDS-**

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

**CONTACTS:**

Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Claire LaCagnina, U.S. Media Contact, +1 315.765.1462, [clacagnina@6degreespr.com](mailto:clacagnina@6degreespr.com)



**About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus MSCs into Phase 2 trials for GvHD (with licensee Fujifilm), severe complications arising from COVID-19 and critical limb ischemia, and into a Phase 3 clinical trial in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ MSC technology in preclinical models of asthma, diabetic wounds, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics Limited**

Level 3, 62 Lygon Street, Carlton, Victoria 3053, Australia  
PO Box 7165, Hawthorn North, Victoria 3122

**T:** + 613 9824 5254 **F:** + 613 9822 7735 **E:** [info@cynata.com](mailto:info@cynata.com)

**ABN** - 98 104 037 372